NXL (Nexalin Technology) Margin of Safety % (DCF Dividends Based): N/A (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NXL Nexalin Technology Inc NXL
38 GF Score
Price $0.33
GF Value $0.66
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Nexalin Technology Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Nexalin Technology's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

NXL vs ICCM, ADGM, ALRTF: Margin of Safety % (DCF Dividends Based) Comparison

For the Medical Devices subindustry, Nexalin Technology's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nexalin Technology Margin of Safety % (DCF Dividends Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nexalin Technology's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Nexalin Technology's Margin of Safety % (DCF Dividends Based) falls into.


NXL
38GF Score
Nexalin Technology Inc NXL
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nexalin Technology (NXL) Overvalued in 2026?

Based on GuruFocus' analysis, Nexalin Technology stock appears to be undervalued. The current stock price of $0.33 is trading 49.6% below its estimated GF Value™ of $0.66. GuruFocus considers Nexalin Technology to be Possible Value Trap.

Key valuation signals for NXL:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $0.66 vs. price of $0.33 (49.6% below fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the NXL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nexalin Technology Business Description

Address 1776 Yorktown, Suite 550, Houston, TX, USA, 77056
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
38GF Score

Get the complete analysis for NXL

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price
$0.66
GF Value